Ask AI
ProCE Banner Activity

Evolving Switch Options Slides: Putting Doravirine/Islatravir’s Approval in Context

Slideset

Download these slides to learn the latest on ART switch strategies for people living with virologically suppressed HIV, including how the recent approval of doravirine/islatravir could affect the treatment landscape.

Released: April 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with American Academy of HIV Medicine, Association of Nurses in AIDS Care (ANAC), and HealthHIV.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of HIV Medicine

ProCE Banner

ANAC

ProCE Banner

HealthHIV

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and advanced practice professionals who provide HIV care in specialist or primary care settings.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise management strategies that integrate the recently approved doravirine/islatravir into the current landscape of ART switch options for the treatment of HIV